3 results
Approved WMOPending
The main objective of this Phase IIa/b study is to demonstrate the effectof zibotentan on HVPG, and that dapagliflozin can mitigate fluid retention safety concernsregarding its use in this population.
Approved WMOCompleted
To investigate the safety and tolerability, and to characterise the pharmacokinetics (PK) of RGH-338 in healthy subjects
Approved WMOCompleted
· To evaluate the effect of zibotentan anddapagliflozin in combination and alone versusplacebo on UACR.